Unicycive Therapeutics Statistics
Share Statistics
Unicycive Therapeutics has 103.80M shares outstanding. The number of shares has increased by 171.49% in one year.
| Shares Outstanding | 103.80M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 150.9% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 87.47M |
| Failed to Deliver (FTD) Shares | 12.21K |
| FTD / Avg. Volume | 0.74% |
Short Selling Information
The latest short interest is 1.05M, so 1.02% of the outstanding shares have been sold short.
| Short Interest | 1.05M |
| Short % of Shares Out | 1.02% |
| Short % of Float | 1.23% |
| Short Ratio (days to cover) | 0.74 |
Valuation Ratios
The PE ratio is -0.7 and the forward PE ratio is -2.42.
| PE Ratio | -0.7 |
| Forward PE | -2.42 |
| PS Ratio | 31.54 |
| Forward PS | 2.3 |
| PB Ratio | -5.59 |
| P/FCF Ratio | -1.16 |
| PEG Ratio | n/a |
Enterprise Valuation
Unicycive Therapeutics Inc. has an Enterprise Value (EV) of 12.40M.
| EV / Earnings | -0.41 |
| EV / Sales | 18.37 |
| EV / EBITDA | -0.41 |
| EV / EBIT | -0.6 |
| EV / FCF | -0.68 |
Financial Position
The company has a current ratio of 0.76, with a Debt / Equity ratio of 0.
| Current Ratio | 0.76 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | -0.47 |
| Cash Flow / Debt | -1015.72 |
| Interest Coverage | -253.34 |
Financial Efficiency
Return on equity (ROE) is 8.02% and return on capital (ROIC) is 692.93%.
| Return on Equity (ROE) | 8.02% |
| Return on Assets (ROA) | -2.15% |
| Return on Capital (ROIC) | 692.93% |
| Revenue Per Employee | 48.21K |
| Profits Per Employee | -2.18M |
| Employee Count | 14 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 24.06% in the last 52 weeks. The beta is 2.29, so Unicycive Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.29 |
| 52-Week Price Change | 24.06% |
| 50-Day Moving Average | 0.53 |
| 200-Day Moving Average | 0.72 |
| Relative Strength Index (RSI) | 60.99 |
| Average Volume (20 Days) | 1.64M |
Income Statement
In the last 12 months, Unicycive Therapeutics had revenue of $675.00K and earned -$30.54M in profits. Earnings per share was $-1.28.
| Revenue | 675.00K |
| Gross Profit | 675.00K |
| Operating Income | -20.77M |
| Net Income | -30.54M |
| EBITDA | -30.18M |
| EBIT | -20.77M |
| Earnings Per Share (EPS) | -1.28 |
Balance Sheet
The company has $9.70M in cash and $811.00K in debt, giving a net cash position of $8.89M.
| Cash & Cash Equivalents | 9.70M |
| Total Debt | 811.00K |
| Net Cash | 8.89M |
| Retained Earnings | -64.54M |
| Total Assets | 38.57M |
| Working Capital | 27.28M |
Cash Flow
In the last 12 months, operating cash flow was -$18.28M and capital expenditures -$12.00K, giving a free cash flow of -$18.30M.
| Operating Cash Flow | -18.28M |
| Capital Expenditures | -12.00K |
| Free Cash Flow | -18.30M |
| FCF Per Share | -0.75 |
Margins
Gross margin is 100%, with operating and profit margins of -3.08K% and -4.53K%.
| Gross Margin | 100% |
| Operating Margin | -3.08K% |
| Pretax Margin | -4.53K% |
| Profit Margin | -4.53K% |
| EBITDA Margin | -4.47K% |
| EBIT Margin | -3.08K% |
| FCF Margin | -2.71K% |
Dividends & Yields
UNCY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -180.28% |
| FCF Yield | -24.68% |
Analyst Forecast
The average price target for UNCY is $5, which is 604.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 604.2% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -0.84 |
| Piotroski F-Score | 2 |